Abstract
Goal Eosinophilic esophagitis (EoE) is an allergic inflammatory condition characterized by eosinophil accumulation in the esophageal mucosa. EoE diagnosis includes a manual assessment of eosinophil levels in mucosal biopsies—a time-consuming, laborious task that is difficult to standardize. One of the main challenges in automating this process, like many other biopsy-based diagnostics, is detecting features that are small relative to the size of the biopsy.
Results In this work, we utilized hematoxylin- and eosin-stained slides from esophageal biopsies from patients with active EoE and control subjects to develop a platform based on a deep convolutional neural network (DCNN) that can classify esophageal biopsies with an accuracy of 85%, sensitivity of 82.5%, and specificity of 87%. Moreover, by combining several downscaling and cropping strategies, we show that some of the features contributing to the correct classification are global rather than specific, local features.
Conclusions We report the ability of artificial intelligence to identify EoE using computer vision analysis of esophageal biopsy slides. Further, the DCNN features associated with EoE are based on not only local eosinophils but also global histologic changes. Our approach can be used for other conditions that rely on biopsy-based histologic diagnostics.
Impact Statement Deep convolutional neural network (DCNN), together with a systematic downscaling approach, can classify esophageal biopsies with high accuracy and reveals a global nature of the histologic features of eosinophilic esophagitis. Our approach of systematic analysis of the image size versus downscaling tradeoff can be used to improve disease classification performance and insight gathering in digital pathology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Y.S. was supported by the American Federation for Aging Research, Israel Science Foundation #1619/20, Rappaport Foundation, The Prince Center for Neurodegenerative Disorders of the Brain #828931. M.E.R. was supported by NIH R01 AI045898-21, the CURED Foundation and Dave and Denise Bunning Sunshine Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed under the Cincinnati Childrens Hospital Medical Center (CCHMC) IRB protocol 2008-0090.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
N/A